Search results for "Venous thromboembolism"
Patients with provoked VTE often on anticoagulation longer than recommended
Three variables were associated with receiving anticoagulation for longer than three months after a provoked venous thromboembolism (VTE): direct oral anticoagulant use, history of VTE, and history of myocardial infarction.
1 Nov 2022
Managing DOACs in primary care
Primary care physicians play a crucial role in ongoing anticoagulation management, including educating patients about the signs of venous thromboembolism.
1 Apr 2022
MKSAP Quiz: 2-year history of worsening hot flashes
A 56-year-old woman is evaluated for a 2-year history of worsening hot flashes and night sweats. She reports that the night sweats awaken her several times nightly, resulting in fatigue and missed work. Following a physical exam, what is the most appropriate treatment?
20 Dec 2022
Latest COVID-19 research on VTE risk, treatment with metformin, ivermectin, fluvoxamine
Unvaccinated patients may have higher risk of venous thromboembolism (VTE) when mildly ill, one study found, while another showed no effect from metformin, ivermectin, or fluvoxamine. Research supported the safety of the mRNA vaccines, and the NIH updated its treatment guidelines.
23 Aug 2022
New resource offers pearls for perioperative medicine
A recent book addresses perioperative medicine, including how to be a perioperative consultant, prophylaxis for venous thromboembolism, coexisting medical problems, and common postoperative complications.
1 Feb 2022
Apixaban shows superior effectiveness, safety compared to rivaroxaban
For patients with venous thromboembolism, initiation of apixaban was associated with lower rates of recurrence and intracranial and gastrointestinal bleeding than rivaroxaban in a population-based cohort study.
7 Dec 2021
Pros, cons of prolonged anticoagulation after a clot
Experts debate about provoked vs. unprovoked venous thromboembolism, and whether a once-high-risk patient can have that status removed later.
1 Feb 2020
DOACs may be safe, effective for VTE prevention in patients with higher weight, BMI
Patients with first-time venous thromboembolism (VTE) who weighed 120 kg or more and had a body mass index (BMI) of 40 kg/m2 or more were not at higher risk for bleeding or recurrent VTE with direct-acting oral anticoagulants (DOACs) versus warfarin.
9 Nov 2021
Long-term anticoagulation after first unprovoked VTE associated with considerable bleeding risk
Results from a systematic review and meta-analysis provide a framework for clinicians and patients to balance the benefits and harms of extended anticoagulation for unprovoked venous thromboembolism (VTE).
14 Sep 2021
MKSAP Quiz: ED evaluation for midsternal pain
A 59-year-old woman is evaluated in the emergency department for midsternal chest pain. The pain began several hours ago as a vague ache in her left upper sternal region that progressed in intensity and severity. The pain abated spontaneously after approximately 45 minutes. She had no further chest pain until several hours later, when it recurred unprovoked by exertion. She has no shortness of breath, nausea or vomiting, syncope, previous history of chest pain, or known cardiac disease or risk factors for venous thromboembolism. Medical history is significant for hyperlipidemia and hypertension. She does not smoke cigarettes. Medications are simvastatin, aspirin, lisinopril, and hydrochlorothiazide. Following a physical exam, electrocardiogram and chest radiograph, what is the most appropriate initial management?.
1 Apr 2014